Stock info Akebia Therapeutics | Filter  Basic-Info

Akebia Therapeutics

The past year yielded positive returns for Akebia Therapeutics investors

The stock lost over the past 12 months at around 21 percent. Over the period 2011-2016 the stock lost a modest 0 percent. Akebia Therapeutics's net incomes between 2011 and 2015 were very volatile through the time and moved between -15,3 million dollars and -60,72 million dollars.

Akebia Therapeutics's head office is located in Cambridge. The company mostly operates in the health care eq. & services sector. Akebia Therapeutics is being led by CEO Mr. John P. Butler. Mr. Jason A. Amello leads the company as CFO. The global health care companies gained around 102 percent worldwide over the last 10 years. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-December 2016) there is a plus of 102 percent.

The American company didn't pay out any dividends (in the past 5 years).

Akebia Therapeutics financed with lots of debt

As per the end of 2015 the American company's balance sheet equaled 142,94 million dollars. Last year the total debt of the company was 11,94 million dollars. This equals around 8,35 percent of the total balance sheet. Last year the health care company's price/earnings-ratio (PE) was around -5. So the investors valued the stock at -5 times 2015' earnings per share. We could say that based on her price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the health care company's market capitalization (the number of shares times the market price) equaled around 332,45 million dollars. At the end of 2015 the American company had around 26,47 million stocks listed.

At this page you find all Akebia Therapeutics's financial reports. More information about Akebia Therapeutics can be found it's website. .